CLINUVEL progresses vitiligo study
CLINUVEL today announced that it will start treatment of vitiligo patients with...
Read More
Notification regarding unquoted securities
Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Positive final results in stroke
CLINUVEL today released positive final results of the open label pilot study...
Read More
CEO letter
For the benefit of the 2.5% recently joined shareholders, I distinguish CLINUVEL’s...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Notice of ceasing to be a substantial holder
Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Initial Director’s Interest Notice
Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL appoints new Non-Executive Director
Melbourne, Australia, 04 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL Extends Employment Agreement With CEO
CLINUVEL today announced that it has extended the Employment Agreement with the...
Read More
DNA Repair Communiqué II
In this DNA Repair Communiqué II we delve deeper into the topic...
Read More
First XP-V Patient Treated in CLINUVEL DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read More
Change of Director's Interest Notice
Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More